NASDAQ:SLN Silence Therapeutics Q1 2026 Earnings Results & Report $9.07 +0.20 (+2.29%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more. Silence Therapeutics missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 8, 2026. The company reported EPS of -$0.32 versus the -$0.1850 consensus estimate, while revenue of $0.42 million fell short of the $1.26 million estimate by $0.83 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 8, 2026TimeBefore Market OpensConference Call DateMay 7, 2026Conference Call8:00 AM ET Silence Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.1850Beat/MissMissed by -$0.1350One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersSilence Therapeutics Revenue ResultsActual Revenue$0.42 millionExpected Revenue$1.26 millionBeat/MissMissed by -$833.00 thousandYoY Revenue GrowthN/AUpcoming EarningsSilence Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Silence Therapeutics Q1 2026 Earnings FAQ Did Silence Therapeutics beat earnings estimates for Q1 2026? Silence Therapeutics (NASDAQ:SLN) reported earnings of -$0.32 per share for Q1 2026, missing the consensus estimate of -$0.1850. The report was announced on Friday, May 8, 2026. What was Silence Therapeutics' revenue for Q1 2026? Silence Therapeutics reported revenue of $0.42 million for Q1 2026, against a consensus estimate of $1.26 million. When is Silence Therapeutics' next earnings date? Silence Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Silence Therapeutics on the company's earnings history page. Silence Therapeutics Earnings HeadlinesSilence Therapeutics (NASDAQ:SLN) Stock Price Down 5.1% - Here's WhyOctober 5, 2026 | americanbankingnews.comFinancial Review: MiMedx Group (NASDAQ:MDXG) vs. Silence Therapeutics (NASDAQ:SLN)October 5, 2026 | americanbankingnews.comMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comSilence Therapeutics: Making Some Recent NoiseAugust 19, 2026 | seekingalpha.comSilence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSsAugust 14, 2026 | businesswire.comSee More Silence Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silence Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your email. Email Address About Silence TherapeuticsSilence Therapeutics (NASDAQ:SLN) plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company’s approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins. Silence’s research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines. The company’s pipeline has included zerlasiran, formerly known as SLN360, an investigational therapy designed to reduce production of lipoprotein(a), a genetically determined cardiovascular risk factor, as well as programs targeting other diseases involving blood disorders and metabolic or cardiovascular pathways. Founded in the United Kingdom, Silence Therapeutics is headquartered in London and serves international markets through its research, clinical-development and commercial collaborations. The company’s shares trade on the Nasdaq Global Select Market under the symbol SLN. Silence continues to advance its proprietary pipeline and partnerships as it works toward developing RNAi-based treatments for patients with serious diseases.View Silence Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
